Tyler Van Buren
Stock Analyst at TD Cowen
(2.33)
# 2,624
Out of 5,241 analysts
65
Total ratings
46.15%
Success rate
-0.46%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $60 | $42.59 | +40.88% | 3 | May 5, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $880 → $960 | $698.25 | +37.49% | 8 | Apr 23, 2026 | |
| SLNO Soleno Therapeutics | Downgrades: Hold | $85 → $53 | $53.01 | -0.02% | 2 | Apr 7, 2026 | |
| BHVN Biohaven | Maintains: Buy | $15 → $30 | $8.76 | +242.47% | 4 | Mar 11, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $35 | $21.32 | +64.17% | 1 | Feb 26, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $40 → $45 | $48.41 | -7.04% | 3 | Feb 13, 2026 | |
| CCCC C4 Therapeutics | Initiates: Buy | n/a | $3.56 | - | 1 | Dec 2, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | n/a | $32.45 | - | 1 | Nov 4, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $95 | $66.13 | +43.66% | 2 | Oct 30, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $115 → $125 | $129.58 | -3.53% | 6 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $28.21 | - | 1 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $66.93 | - | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $10.50 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $20.23 | - | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $61.93 | - | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $70 → $60 | $49.04 | +22.35% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $9.78 | - | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $7.38 | - | 1 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $27.89 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $35.44 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $74.92 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $81.14 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.76 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $28.05 | +149.55% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.05 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.08 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $37.04 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $19.98 | +1,026.13% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $5.71 | +15,223.99% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $15.86 | +152.29% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $16.22 | +84.96% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.15 | +4,247.83% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.34 | +8,723.53% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.25 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $34.29 | - | 1 | Aug 4, 2017 |
Travere Therapeutics
May 5, 2026
Maintains: Buy
Price Target: $45 → $60
Current: $42.59
Upside: +40.88%
Regeneron Pharmaceuticals
Apr 23, 2026
Maintains: Buy
Price Target: $880 → $960
Current: $698.25
Upside: +37.49%
Soleno Therapeutics
Apr 7, 2026
Downgrades: Hold
Price Target: $85 → $53
Current: $53.01
Upside: -0.02%
Biohaven
Mar 11, 2026
Maintains: Buy
Price Target: $15 → $30
Current: $8.76
Upside: +242.47%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $35
Current: $21.32
Upside: +64.17%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Hold
Price Target: $40 → $45
Current: $48.41
Upside: -7.04%
C4 Therapeutics
Dec 2, 2025
Initiates: Buy
Price Target: n/a
Current: $3.56
Upside: -
MBX Biosciences
Nov 4, 2025
Initiates: Buy
Price Target: n/a
Current: $32.45
Upside: -
BridgeBio Pharma
Oct 30, 2025
Maintains: Buy
Price Target: $60 → $95
Current: $66.13
Upside: +43.66%
Gilead Sciences
Oct 23, 2025
Maintains: Buy
Price Target: $115 → $125
Current: $129.58
Upside: -3.53%
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $28.21
Upside: -
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $66.93
Upside: -
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $10.50
Upside: -
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $20.23
Upside: -
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $61.93
Upside: -
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $49.04
Upside: +22.35%
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $9.78
Upside: -
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $7.38
Upside: -
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $27.89
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $35.44
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $74.92
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $81.14
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.76
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $28.05
Upside: +149.55%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $4.05
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.08
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $37.04
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $19.98
Upside: +1,026.13%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $5.71
Upside: +15,223.99%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $15.86
Upside: +152.29%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $16.22
Upside: +84.96%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.15
Upside: +4,247.83%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $0.34
Upside: +8,723.53%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $12.25
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $34.29
Upside: -